A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Phase 1

Completed

Brief Summary: Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens.

Detailed Description: The optional followup period for this study is 1 year after the last vaccination.

Recruitment & Eligibility

Inclusion Criteria

Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment
Patient must not be pregnant 3 days prior to enrollment

Exclusion Criteria

Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
Patient has had their spleen removed or has a history of autoimmune disorders
Patient is a regular user of any illicit drugs or has used within the past year of drug or alcohol abuse
Patient is pregnant or breastfeeding or is expecting to conceive anytime following the study
Patient is known to be Human Immunodeficiency Virus (HIV)-seropositive
Patient has a known history of Hepatitis B or C
Patient has received a vaccine for any disease or condition within one month of enrollment
Patient has a primary central nervous system tumor.

Arm && Interventions

Group	Intervention	Description
1	V930	V930
2	V932	V932

Primary Outcome Measures

Name	Time	Method
To determine the safety and tolerability of V930/V932 followed by EP in cancer patients	Week 22

Secondary Outcome Measures

Name	Time	Method
To determine whether V930/V932 can elicit HER-2 specific and CEA specific immune responses measured using an ELISPOT assay	Week 22

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial